The use of 18f-fluorodeoxyglucose positron emission tomography to assess clinical outcomes of patients wıth borderline resectable pancreatic cancer

Basit Öğe Kaydı
dc.contributor.authorDurmuş, Ali
dc.contributor.authorYılmaz, Ahmet
dc.contributor.authorMalya, Fatma Ümit
dc.contributor.authorÖztürk, Gökmen
dc.contributor.authorBektaşo?lu, Hüseyin Kazım
dc.contributor.authorErtuğrul, G.
dc.contributor.authorKaryağar Sağlampınar, Sevda
dc.contributor.authorKaratepe, O?uzhan
dc.date.accessioned2020-08-12T09:11:14Z
dc.date.available2020-08-12T09:11:14Z
dc.date.issued2016
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Genel Cerrahi Ana Bilim Dalı
dc.description.abstractThe aim of this study is to evaluate the effect of 18FDG PET on preoperative staging and clinical management of pancreatic cancer. Between December 2011 and February 2015, 28 consecutive patients with borderline resectable pancreatic cancer were evaluated with both 18FDG PET scans and conventional preoperative imaging studies. Medical records of all patients were noted prospectively. 18FDG PET findings were compared with conventional imaging studies and over-staging or down-staging rates with changes in clinical management were evaluated. The correlation of 18FDG PET with conventional imaging studies was evaluated with a kappa agreement coefficient. A number of 22 (78.5%) patients had pancreatic head cancer and 6 (21.4%) patients had pancreatic body and tail cancers. Based on 18FDG PET, additional lesions were found in 4 (14.28%) of the patients which were lung and peritoneal lesions as metastasis. No hepatic metastasis or supraclavicular lymph node involvement was confirmed in patients. Routine use of 18FDG PET for preoperative staging has not an effect on cancer management in 96.8% of our patients. In conclusion, 18FDG PET has additional value over conventional radiologic techniques for monitoring the treatment response in locally advanced pancreatic cancer patients. It is feasible to predict early metastasis and patient outcome early (after one course of IC) during therapy.
dc.identifier.citationDurmuş, A., Yılmaz, A., Malya, F. Ü., Öztürk, G., Bektaşo?lu, H. K., Ertuğrul, G. ... Karatepe, O. (2016). The use of 18f-fluorodeoxyglucose positron emission tomography to assess clinical outcomes of patients wıth borderline resectable pancreatic cancer, 253, 26-29.
dc.identifier.endpage29
dc.identifier.issn1512-0112
dc.identifier.issue253
dc.identifier.scopusqualityQ4
dc.identifier.startpage26
dc.identifier.urihttps://hdl.handle.net/20.500.12511/5698
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherGeorgian Association of Business Press
dc.relation.ispartofGeorgian Medical Newsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectFluorodeoxyglucose
dc.subjectTomography
dc.subjectPancreatic Cancer
dc.titleThe use of 18f-fluorodeoxyglucose positron emission tomography to assess clinical outcomes of patients wıth borderline resectable pancreatic cancer
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
durmus, ali-2016.pdf
Boyut:
1.97 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu